Developments in biobanking workflow standardization providing sample integrity and stability

Johan Malm, Thomas E. Fehniger, Pia Danmyr, Ákos Végvári, Charlotte Welinder, Henrik Lindberg, Roger Appelqvist, Karin Sjödin, Elisabet Wieslander, Thomas Laurell, Sophia Hober, Frode S. Berven, David Fenyö, Xiangdong Wang, Per E. Andrén, Goutham Edula, Elisabet Carlsohn, Manuel Fuentes, Carol L. Nilsson, Magnus Dahlbäck & 3 others Melinda Rezeli, David Erlinge, György Marko-Varga

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Recommendations and outlines for standardization in biobanking processes are presented by a research team with long-term experience in clinical studies. These processes have important bearing on the use of samples in developing assays. These measurements are useful to document states of health and disease that are beneficial for academic research, commercial healthcare, drug development industry and government regulating agencies. There is a need for increasing awareness within proteomic and genomic communities regarding the basic concepts of collecting, storing and utilizing clinical samples. Quality control and sample suitability for analysis need to be documented and validated to ensure data integrity and establish contexts for interpretation of results. Standardized methods in proteomics and genomics are required to be practiced throughout the community allowing datasets to be comparable and shared for analysis. For example, sample processing of thousands of clinical samples, performed in 384 high-density sample tube systems in a fully automated workflow, preserves sample content and is presented showing validation criteria. Large studies will be accompanied by biological and molecular information with corresponding clinical records from patients and healthy donors. These developments position biobanks of human patient samples as an increasingly recognized major asset in disease research, future drug development and within patient care. Biological significance: The current manuscript is of major relevance to the proteomic and genomic fields, as it outlines the standardization aspects of biobanking and the requirements that are needed to run future clinical studies that will benefit the patients where OMICS science will play a major role. A global view of the field is given where best practice and conventional acceptances are presented along with ongoing large-scale biobanking projects. The authors represent broadly stakeholders that cover the academic, pharma, biotech and healthcare fields with extensive experience and deliveries. This contribution will be a milestone paper to the proteomic and genomic scientists to present data in the future that will have impact to the life science area.This article is part of a Special Issue entitled: Standardization and Quality Control in Proteomics.

Original languageEnglish (US)
Pages (from-to)38-45
Number of pages8
JournalJournal of Proteomics
Volume95
DOIs
StatePublished - Dec 16 2013

Fingerprint

Workflow
Proteomics
Standardization
Quality Control
Quality control
Bearings (structural)
Government Agencies
Biological Science Disciplines
Manuscripts
Health Services Research
Drug Industry
Genomics
Practice Guidelines
Research
Pharmaceutical Preparations
Assays
Patient Care
Health
Tissue Donors
Delivery of Health Care

Keywords

  • Antibodies
  • Biobank
  • Diseases
  • Mass spectrometry
  • Proteins
  • Standardization

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics

Cite this

Malm, J., Fehniger, T. E., Danmyr, P., Végvári, Á., Welinder, C., Lindberg, H., ... Marko-Varga, G. (2013). Developments in biobanking workflow standardization providing sample integrity and stability. Journal of Proteomics, 95, 38-45. https://doi.org/10.1016/j.jprot.2013.06.035

Developments in biobanking workflow standardization providing sample integrity and stability. / Malm, Johan; Fehniger, Thomas E.; Danmyr, Pia; Végvári, Ákos; Welinder, Charlotte; Lindberg, Henrik; Appelqvist, Roger; Sjödin, Karin; Wieslander, Elisabet; Laurell, Thomas; Hober, Sophia; Berven, Frode S.; Fenyö, David; Wang, Xiangdong; Andrén, Per E.; Edula, Goutham; Carlsohn, Elisabet; Fuentes, Manuel; Nilsson, Carol L.; Dahlbäck, Magnus; Rezeli, Melinda; Erlinge, David; Marko-Varga, György.

In: Journal of Proteomics, Vol. 95, 16.12.2013, p. 38-45.

Research output: Contribution to journalArticle

Malm, J, Fehniger, TE, Danmyr, P, Végvári, Á, Welinder, C, Lindberg, H, Appelqvist, R, Sjödin, K, Wieslander, E, Laurell, T, Hober, S, Berven, FS, Fenyö, D, Wang, X, Andrén, PE, Edula, G, Carlsohn, E, Fuentes, M, Nilsson, CL, Dahlbäck, M, Rezeli, M, Erlinge, D & Marko-Varga, G 2013, 'Developments in biobanking workflow standardization providing sample integrity and stability', Journal of Proteomics, vol. 95, pp. 38-45. https://doi.org/10.1016/j.jprot.2013.06.035
Malm, Johan ; Fehniger, Thomas E. ; Danmyr, Pia ; Végvári, Ákos ; Welinder, Charlotte ; Lindberg, Henrik ; Appelqvist, Roger ; Sjödin, Karin ; Wieslander, Elisabet ; Laurell, Thomas ; Hober, Sophia ; Berven, Frode S. ; Fenyö, David ; Wang, Xiangdong ; Andrén, Per E. ; Edula, Goutham ; Carlsohn, Elisabet ; Fuentes, Manuel ; Nilsson, Carol L. ; Dahlbäck, Magnus ; Rezeli, Melinda ; Erlinge, David ; Marko-Varga, György. / Developments in biobanking workflow standardization providing sample integrity and stability. In: Journal of Proteomics. 2013 ; Vol. 95. pp. 38-45.
@article{7314cbea03634607855d0d96a60c673d,
title = "Developments in biobanking workflow standardization providing sample integrity and stability",
abstract = "Recommendations and outlines for standardization in biobanking processes are presented by a research team with long-term experience in clinical studies. These processes have important bearing on the use of samples in developing assays. These measurements are useful to document states of health and disease that are beneficial for academic research, commercial healthcare, drug development industry and government regulating agencies. There is a need for increasing awareness within proteomic and genomic communities regarding the basic concepts of collecting, storing and utilizing clinical samples. Quality control and sample suitability for analysis need to be documented and validated to ensure data integrity and establish contexts for interpretation of results. Standardized methods in proteomics and genomics are required to be practiced throughout the community allowing datasets to be comparable and shared for analysis. For example, sample processing of thousands of clinical samples, performed in 384 high-density sample tube systems in a fully automated workflow, preserves sample content and is presented showing validation criteria. Large studies will be accompanied by biological and molecular information with corresponding clinical records from patients and healthy donors. These developments position biobanks of human patient samples as an increasingly recognized major asset in disease research, future drug development and within patient care. Biological significance: The current manuscript is of major relevance to the proteomic and genomic fields, as it outlines the standardization aspects of biobanking and the requirements that are needed to run future clinical studies that will benefit the patients where OMICS science will play a major role. A global view of the field is given where best practice and conventional acceptances are presented along with ongoing large-scale biobanking projects. The authors represent broadly stakeholders that cover the academic, pharma, biotech and healthcare fields with extensive experience and deliveries. This contribution will be a milestone paper to the proteomic and genomic scientists to present data in the future that will have impact to the life science area.This article is part of a Special Issue entitled: Standardization and Quality Control in Proteomics.",
keywords = "Antibodies, Biobank, Diseases, Mass spectrometry, Proteins, Standardization",
author = "Johan Malm and Fehniger, {Thomas E.} and Pia Danmyr and {\'A}kos V{\'e}gv{\'a}ri and Charlotte Welinder and Henrik Lindberg and Roger Appelqvist and Karin Sj{\"o}din and Elisabet Wieslander and Thomas Laurell and Sophia Hober and Berven, {Frode S.} and David Feny{\"o} and Xiangdong Wang and Andr{\'e}n, {Per E.} and Goutham Edula and Elisabet Carlsohn and Manuel Fuentes and Nilsson, {Carol L.} and Magnus Dahlb{\"a}ck and Melinda Rezeli and David Erlinge and Gy{\"o}rgy Marko-Varga",
year = "2013",
month = "12",
day = "16",
doi = "10.1016/j.jprot.2013.06.035",
language = "English (US)",
volume = "95",
pages = "38--45",
journal = "Journal of Proteomics",
issn = "1874-3919",
publisher = "Elsevier",

}

TY - JOUR

T1 - Developments in biobanking workflow standardization providing sample integrity and stability

AU - Malm, Johan

AU - Fehniger, Thomas E.

AU - Danmyr, Pia

AU - Végvári, Ákos

AU - Welinder, Charlotte

AU - Lindberg, Henrik

AU - Appelqvist, Roger

AU - Sjödin, Karin

AU - Wieslander, Elisabet

AU - Laurell, Thomas

AU - Hober, Sophia

AU - Berven, Frode S.

AU - Fenyö, David

AU - Wang, Xiangdong

AU - Andrén, Per E.

AU - Edula, Goutham

AU - Carlsohn, Elisabet

AU - Fuentes, Manuel

AU - Nilsson, Carol L.

AU - Dahlbäck, Magnus

AU - Rezeli, Melinda

AU - Erlinge, David

AU - Marko-Varga, György

PY - 2013/12/16

Y1 - 2013/12/16

N2 - Recommendations and outlines for standardization in biobanking processes are presented by a research team with long-term experience in clinical studies. These processes have important bearing on the use of samples in developing assays. These measurements are useful to document states of health and disease that are beneficial for academic research, commercial healthcare, drug development industry and government regulating agencies. There is a need for increasing awareness within proteomic and genomic communities regarding the basic concepts of collecting, storing and utilizing clinical samples. Quality control and sample suitability for analysis need to be documented and validated to ensure data integrity and establish contexts for interpretation of results. Standardized methods in proteomics and genomics are required to be practiced throughout the community allowing datasets to be comparable and shared for analysis. For example, sample processing of thousands of clinical samples, performed in 384 high-density sample tube systems in a fully automated workflow, preserves sample content and is presented showing validation criteria. Large studies will be accompanied by biological and molecular information with corresponding clinical records from patients and healthy donors. These developments position biobanks of human patient samples as an increasingly recognized major asset in disease research, future drug development and within patient care. Biological significance: The current manuscript is of major relevance to the proteomic and genomic fields, as it outlines the standardization aspects of biobanking and the requirements that are needed to run future clinical studies that will benefit the patients where OMICS science will play a major role. A global view of the field is given where best practice and conventional acceptances are presented along with ongoing large-scale biobanking projects. The authors represent broadly stakeholders that cover the academic, pharma, biotech and healthcare fields with extensive experience and deliveries. This contribution will be a milestone paper to the proteomic and genomic scientists to present data in the future that will have impact to the life science area.This article is part of a Special Issue entitled: Standardization and Quality Control in Proteomics.

AB - Recommendations and outlines for standardization in biobanking processes are presented by a research team with long-term experience in clinical studies. These processes have important bearing on the use of samples in developing assays. These measurements are useful to document states of health and disease that are beneficial for academic research, commercial healthcare, drug development industry and government regulating agencies. There is a need for increasing awareness within proteomic and genomic communities regarding the basic concepts of collecting, storing and utilizing clinical samples. Quality control and sample suitability for analysis need to be documented and validated to ensure data integrity and establish contexts for interpretation of results. Standardized methods in proteomics and genomics are required to be practiced throughout the community allowing datasets to be comparable and shared for analysis. For example, sample processing of thousands of clinical samples, performed in 384 high-density sample tube systems in a fully automated workflow, preserves sample content and is presented showing validation criteria. Large studies will be accompanied by biological and molecular information with corresponding clinical records from patients and healthy donors. These developments position biobanks of human patient samples as an increasingly recognized major asset in disease research, future drug development and within patient care. Biological significance: The current manuscript is of major relevance to the proteomic and genomic fields, as it outlines the standardization aspects of biobanking and the requirements that are needed to run future clinical studies that will benefit the patients where OMICS science will play a major role. A global view of the field is given where best practice and conventional acceptances are presented along with ongoing large-scale biobanking projects. The authors represent broadly stakeholders that cover the academic, pharma, biotech and healthcare fields with extensive experience and deliveries. This contribution will be a milestone paper to the proteomic and genomic scientists to present data in the future that will have impact to the life science area.This article is part of a Special Issue entitled: Standardization and Quality Control in Proteomics.

KW - Antibodies

KW - Biobank

KW - Diseases

KW - Mass spectrometry

KW - Proteins

KW - Standardization

UR - http://www.scopus.com/inward/record.url?scp=84888305959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888305959&partnerID=8YFLogxK

U2 - 10.1016/j.jprot.2013.06.035

DO - 10.1016/j.jprot.2013.06.035

M3 - Article

VL - 95

SP - 38

EP - 45

JO - Journal of Proteomics

JF - Journal of Proteomics

SN - 1874-3919

ER -